Particle.news
Download on the App Store

Wegovy Pill Arrives in UK Private Market as Clinicians Flag Dosing and Safety Risks

Private pharmacies are already dispensing the daily oral semaglutide tablet, which changes access patterns, raises monitoring needs, increases counterfeit risk.

Overview

  • The Wegovy tablet has begun to be supplied privately in UK pharmacies this month and early users report mixed results, including renewed hunger and common gastrointestinal side effects.
  • Pharmacists stress the tablet must be taken on an empty stomach with at least a 30‑minute wait before food, drink or other oral medicines because timing and coffee can reduce absorption.
  • Oral semaglutide uses an absorption enhancer and delivers far less drug to the bloodstream than injections, and trials show the pill gives about 17% mean weight loss compared with roughly 21% for higher‑dose injectables.
  • Clinicians warn that side effects remain similar to injectable GLP‑1s, that switching formulations needs medical supervision, and that tablets are easier to counterfeit or sell unsafely online.
  • Routine NHS funding and NICE appraisal are still unresolved, so private availability creates cost‑based access differences that may widen inequality as demand for oral GLP‑1s grows.